bpc 157 human clinical trial dosing bpc-157 protocol BPC-157 Dosing (Common Protocols) πΉ Oral / Subcutaneous β’ 500 mcg daily β’ Duration: 6 weeks πΉ Intramuscular / Peritendinous β’ 1 mg daily β’ Duration: 6 weeks β οΈ Note: Not approved bpc-157 human clinical trials dosing
Description
It is also important for releasing energy from food and using vitamin B11 (folic acid)
Oral or injectable forms
A temperature greater than 37.7 (99.8 F) may indicate infection
Its mostly used in research settings
This overlap with the mTOR axis places MOTS-c in an interesting relationship with The Rapamycin Protocol, the most direct pharmaceutical intervention on the mTOR pathway
Most clinical trials have reported few side effects when taking Thymosin Alpha-1
